Transactions
7
Insider / ABBOTT LABORATORIES
Conroy Kevin T
Director at ABBOTT LABORATORIES
- Company
- ABBOTT LABORATORIES
- First filing on record
- April 28, 2026
- Latest trade on record
- September 30, 2026
- SEC filings
- EDGAR ↗
Conroy Kevin T, Director at ABBOTT LABORATORIES, has disclosed 7 transactions in ABT, ALGN since April 28, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $5.5M at the reported prices. The latest was filed October 2, 2026, 2 days after the trade.
Open-market buys
0
Sales
1
Avg. disclosure lag
2.1d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Conroy Kevin T made no purchases and 1 sale worth $5.5M, plus 6 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Conroy Kevin T has traded 1 stock on record; the largest by dollars is ABT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 4 | 4,671 | $52K |
| M | Option exercise or conversion | 2 | 3,490 | — |
| F | Shares withheld for tax | 1 | 52,507 | $5.5M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 7 | 0 | 1 · $5.5M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ABT | Other A | September 30, 2026 | October 2, 2026 | 2d | 318 | $99 | $31K | derivative | Form 4 ↗ | |
| ABT | Sell F | September 23, 2026 | September 25, 2026 | 2d | 52,507 | $104 | $5.5M | Form 4 ↗ | ||
| ABT | Other A | June 30, 2026 | July 1, 2026 | 1d | 231 | $91 | $21K | derivative | Form 4 ↗ | |
| ALGN | Other A | May 20, 2026 | May 22, 2026 | 2d | 1,836 | — | — | derivative | Form 4 ↗ | |
| ALGN | Option / conversion M | May 20, 2026 | May 22, 2026 | 2d | 1,745 | — | — | derivative | Form 4 ↗ | |
| ALGN | Option / conversion M | May 20, 2026 | May 22, 2026 | 2d | 1,745 | — | — | Form 4 ↗ | ||
| ABT | Other A | April 24, 2026 | April 28, 2026 | 4d | 2,286 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 2, 2026 | Form 4 | 0001104659-26-113286 | 1 | published | EDGAR ↗ |
| September 25, 2026 | Form 4 | 0001306119-26-000009 | 1 | published | EDGAR ↗ |
| July 1, 2026 | Form 4 | 0001306119-26-000006 | 1 | published | EDGAR ↗ |
| May 22, 2026 | Form 4 | 0001193125-26-237321 | 3 | published | EDGAR ↗ |
| April 28, 2026 | Form 4 | 0001306119-26-000004 | 1 | published | EDGAR ↗ |
Other insiders at ABBOTT LABORATORIES
- Vitalone Britt J. EVP & CFO 15 rows
- Stratton John G Director 14 rows
- Coletti Julie Ann Chief Legal Officer 13 rows
- Ford Robert B CHAIRMAN AND CEO 10 rows
- McKinstry Nancy Director 10 rows
- Morici John EVP, CHIEF FINANCIAL OFFICER 10 rows
- O'Grady Michael Chairman and CEO 10 rows
- HOGAN JOSEPH M President and CEO 9 rows
- Hockridge Stuart A EVP, GLOBAL HR 7 rows
- Morrone Louis H. EXECUTIVE VICE PRESIDENT 7 rows
Everyone on file, with contracts and lobbying under the company's name: ABBOTT LABORATORIES.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 7 | April 28, 2026 | October 2, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.